Varian backs Phase III non-small cell lung cancer trial

Varian Medical (NYSE:VAR) said today it is supporting a Phase III clinical trial set to compare outcomes of radiosurgery against surgical resection for treating early-stage, high-risk operable non-small cell lung cancer. The randomized “Stablemates Trial” will test the hypothesis that 3-year overall survival in high risk operable patients with Stage I NSCLC is equivalent or greater in patients who undergo stereotactic ablative radiotherapy compared to conventional surgery, the company said. “In addition to a potentially longer survival rate, SAbR may benefit some lung cancer patients by offering them a noninvasive, outpatient treatment option that is easier to tolerate and that doesn’t interfere greatly with their normal, everyday living activities,” trial co-chair Dr. Robert Timmerman of the University of Texas Southwestern Medical Center said in prepared remarks. The trial has currently enrolled 258 patients at 34 different locations, and is being sponsored by the Joint Lung Cancer Trialist’s Coalition and being administered by the Department of Radiation Oncology at the University of Texas Southwestern Medical Center. The study will examine patient’s overall, disease-free and regional recurrence-free survival rates 3-years post treatment and for up to 5 years observing adverse events and post-treatment quality of life, the Palo Alto, Calif.-based company said. “Varian believes in supporting high quality clinical resear...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Oncology Radiosurgery Varian Medical Systems Source Type: news